Today's Articles:

The View From School Medical school today, from medical students themselves

Personalized Medicine & the Future of Drug Safety Can personalized medicine that incorporates genetic information make prescribing drugs less risky?

Clinical Decision Making Under Conditions of Severe Uncertainty: The Info-Gap Solution

Diversity: It's not what medical schools think
"The American obsession with race reflects itself in its medical schools..."

Bob's Blog: Now I'm Really Worried

Join this blog: E-mail us your comments

Health News:

Breaking Health Articles

Personalized Medicine
and the Future of Drug Safety
By Amalia M. Issa, MPH, PhD

References

1. Wadman M. Drug Safety Special: The Safety Catch," Nature 434: 554-556, 2005.

2. Waxman HA The Lessons of Vioxx - Drug Safety and Sales. New England Journal of Medicine 352: 2576-2578,2005

3. Singh, D. Merck withdraws arthritis drug worldwide. BMJ 329: 816, 2005.

4. Eilers RP. “After Vioxx: Whither drug safety in the U.S. ?” American Public Health Association Annual Meeting, # 120486, Philadelphia , PA , December 14, 2005 .

5. Feinberg JL. “Novel pharmacist interventions to improve medication safety: Using clinical informatics to improve patient safety at the medication monitoring stage,” American Public Health Association Annual Meeting, # 106502, Philadelphia , PA , December 13, 2005 .

6. Field R. Post-market drug surveillance: Options for reform. American Public Health Association Annual Meeting, #105982, Philadelphia , PA , December 14, 2005.

7. Garrod 1902

8. Carsen et al. 1956

9. Kalow and Gunn, 1957

10. Issa, A.M. Perspectives in pharmacogenomic profiling in the drug development process. Nature Rev. Drug Discov . 1: 300-308, 2002.

11. Evans WE and Relling MV.Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286: 487 – 491, 1999.

12. Arledge T, Freeman A, Arbuckle J, Mosteller M, Manasco P. Applications of pharmacogenetics to drug development: The Galxo Wellcome experience. Drug Metab. Rev . 32: 387 – 394, 2000.

13. Kurth JH. Pharmacogenomics: future promise of a tool for identifying patients at risk. Drug Info J . 34: 223-227, 2000.

14. Robbins-Roth, C. From Alchemy to IPO: The Business of Biotechnology , pp. 73-78, Perseus Publishing, Cambridge, MA, 2003.

15. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev. Drug Discov. 1, 541-549, 2002.

16. Shi MM, Bleavins MR, and de la Iglesia FA. Pharmacogenetic application in drug development and clinical trials. Drug Metabolism & Disposition 29, 591-595 , 2001.

17. Primohamed M and Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298- 305, 2001.

18. Güzey C. and Spigset O. Genotyping of drug targets: a method to predict adverse drug reactions? Drug Safety 25, 553-560, 2002.

19. Ingelman-Sundberg M. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philosophical Transactions of The Royal Society B Biological Sciences 360: 1460, 2005.

20. Rodrigues AD and Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr. Drug Metab . 3, 289-309, 2002.

21. Rogers JF, Nafziger AN, and Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. 113: 746-750, 2002.

22. Bernard, 2003

23. Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352: 2211-21, 2005.

24. Farmer JA. Learning from the cerivastatin experience. Lancet 358: 1383-85, 2001.

25. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis . N. Engl. J. Med. 2002; 346: 539-40, 2005.

26. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36: 288-95, 2002.

27. Sica DA, Gehr TW. Rhabdomyolsis and statin therapy: relevance to the elderly. Am. J. Geriatr. Cardiology 11: 48-55, 2002.

28. Grundy SM. The issue of statin safety: Where do we stand? Circulation 111: 3016-19, 2005.

29. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolsis in patients treated with lipid-lowering drugs. JAMA 292: 2585-2590,2004.

30. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Clin. Pharmacol. Ther. 72: 685-691, 2002

31. Prueksaritanont T, Zhao JJ, Ma B, Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther 301: 1042-51, 2002.

32. Phillips KA, Veenstra DL,Oren E,Lee JK, and Sadee W."Potential Role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286: 2270-2279,2001.

33. Issa, A.M. Pharmacogenomic profiling in post-marketing surveillance: Prospects and challenges Pharmacogenomics 4: 647-655, 2003.

34. Hill R, Frankel B. and Kurdikar D. Modeling pharmacogenomics. In Vivo November, 77-79, 2001.

35. Mahowald, M. Genetics in the Clinic: Ethical and Social Implications for Primary Care, 2001.

Return to Article